CN115813985A - A Chinese medicinal capsule for treating cerebral apoplexy and its preparation method - Google Patents
A Chinese medicinal capsule for treating cerebral apoplexy and its preparation method Download PDFInfo
- Publication number
- CN115813985A CN115813985A CN202211668761.5A CN202211668761A CN115813985A CN 115813985 A CN115813985 A CN 115813985A CN 202211668761 A CN202211668761 A CN 202211668761A CN 115813985 A CN115813985 A CN 115813985A
- Authority
- CN
- China
- Prior art keywords
- parts
- extracting solution
- cerebral apoplexy
- preparation
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 35
- 206010008190 Cerebrovascular accident Diseases 0.000 title claims abstract description 29
- 208000006011 Stroke Diseases 0.000 title claims abstract description 29
- 230000002490 cerebral effect Effects 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 55
- 239000000284 extract Substances 0.000 claims abstract description 51
- 239000000463 material Substances 0.000 claims abstract description 25
- 241000545744 Hirudinea Species 0.000 claims abstract description 19
- 238000007873 sieving Methods 0.000 claims abstract description 17
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 15
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 13
- 239000002671 adjuvant Substances 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 9
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 8
- 238000010298 pulverizing process Methods 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 39
- 238000000605 extraction Methods 0.000 claims description 34
- 102000004190 Enzymes Human genes 0.000 claims description 33
- 108090000790 Enzymes Proteins 0.000 claims description 33
- 229940088598 enzyme Drugs 0.000 claims description 33
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 claims description 19
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 17
- 239000011812 mixed powder Substances 0.000 claims description 14
- 239000008055 phosphate buffer solution Substances 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 108090000145 Bacillolysin Proteins 0.000 claims description 10
- 102000029816 Collagenase Human genes 0.000 claims description 10
- 108060005980 Collagenase Proteins 0.000 claims description 10
- 229920001353 Dextrin Polymers 0.000 claims description 10
- 239000004375 Dextrin Substances 0.000 claims description 10
- 102000035092 Neutral proteases Human genes 0.000 claims description 10
- 108091005507 Neutral proteases Proteins 0.000 claims description 10
- 108090000631 Trypsin Proteins 0.000 claims description 10
- 102000004142 Trypsin Human genes 0.000 claims description 10
- 229960002424 collagenase Drugs 0.000 claims description 10
- 235000019425 dextrin Nutrition 0.000 claims description 10
- 239000012588 trypsin Substances 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 9
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 9
- 239000001569 carbon dioxide Substances 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- 102000012286 Chitinases Human genes 0.000 claims description 8
- 108010022172 Chitinases Proteins 0.000 claims description 8
- 235000000346 sugar Nutrition 0.000 claims description 8
- 241000219061 Rheum Species 0.000 claims description 7
- 240000004980 Rheum officinale Species 0.000 claims description 7
- 235000008081 Rheum officinale Nutrition 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 241000255626 Tabanus <genus> Species 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 23
- 210000004369 blood Anatomy 0.000 abstract description 16
- 239000008280 blood Substances 0.000 abstract description 16
- 239000004480 active ingredient Substances 0.000 abstract description 15
- 238000010521 absorption reaction Methods 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 7
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 14
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 10
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 206010028851 Necrosis Diseases 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000017074 necrotic cell death Effects 0.000 description 8
- 238000002791 soaking Methods 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 206010000077 Abdominal mass Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 229940090044 injection Drugs 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010019468 Hemiplegia Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010067347 Thrombotic cerebral infarction Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940093181 glucose injection Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960004526 piracetam Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000205574 Acorus calamus Species 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000489492 Arisaema Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 235000011996 Calamus deerratus Nutrition 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019452 Hemianopia Diseases 0.000 description 1
- 208000007460 Hemianopsia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000208966 Polygala Species 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 241001482963 Thamnophis Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000011279 abdominal lump Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000007946 glucose deprivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The application discloses a traditional Chinese medicine capsule for treating cerebral apoplexy and a preparation method thereof, relating to the technical field of medicines. A Chinese medicinal capsule for treating cerebral apoplexy comprises extractive solution A and extractive solution B; the main components comprise: 10-25 parts of leech, 5-10 parts of gadfly, 20-30 parts of rhubarb and 20-30 parts of peach kernel, and the preparation method of the traditional Chinese medicine capsule comprises the following steps: preparing an extracting solution A and an extracting solution B according to a formula and a preparation method, combining the extracting solution A and the extracting solution B, adding 10-20 parts of medicinal auxiliary materials, uniformly stirring, and drying in vacuum to obtain dry paste; pulverizing the dry extract, adding 4-6 parts of medicinal adjuvants, sieving, mixing, and making into capsule. The application can improve the effect of a patient on the absorption of active ingredients of medicinal materials, effectively treat cerebral apoplexy, and has the effects of removing blood stasis, dredging channels and collaterals.
Description
Technical Field
The application relates to the field of pharmaceutical technology, in particular to a traditional Chinese medicine capsule for treating cerebral apoplexy and a preparation method thereof.
Background
Cerebral apoplexy is an acute cerebrovascular disease, brain tissue damage or dysfunction caused by the inability of blood to flow into the brain due to sudden rupture or blockage of blood vessels in the brain, clinically manifested as symptoms and signs of transient or permanent brain dysfunction, and is an acute disease caused by vascular diseases that transport blood to the brain.
The Chinese medicine has unique advantages for treating cerebral apoplexy, and related technologies can refer to Chinese patent application with publication No. CN102885983A, which discloses a Chinese medicine composition for treating cerebral apoplexy, wherein the medicine composition comprises nineteen Chinese medicines of scorpion, leech, earthworm, calamus, polygala root, garter snake, szechuan lovage rhizome, safflower, arisaema cum bile, stiff silkworm and the like, and is obtained by selecting fruits, drying, crushing, sieving by a 100-mesh sieve and encapsulating.
With respect to the related art in the above, the inventors consider that there are the following drawbacks: the formula components shown in the technical method are mostly used as crude drugs in patent medicines, and the absorption rate of active ingredients of the drugs by patients is low, so that the treatment effect is not good and the cure efficiency is low.
Disclosure of Invention
In order to improve the absorption of active ingredients of the medicine by a patient and enhance the curative effect, the application provides a traditional Chinese medicine capsule for treating cerebral apoplexy and a preparation method thereof.
The application provides a traditional Chinese medicine capsule for treating cerebral apoplexy, which adopts the following technical scheme:
a Chinese medicinal capsule for treating cerebral apoplexy comprises extract A and extract B;
the extracting solution A comprises the following raw materials in parts by weight: 10-25 parts of leech and 5-10 parts of gadfly;
the extract B comprises the following raw materials in parts by weight: 20-30 parts of rhubarb and 20-30 parts of peach kernel.
By adopting the technical scheme, different methods are adopted to extract the active ingredients of the medicinal materials, so that the active ingredients in the medicament are completely extracted, and the absorption of the active ingredients of the medicinal materials by a patient is facilitated, thereby improving the treatment effect of the medicament.
Preferably, the preparation of the extract A comprises the following steps:
weighing 10-25 parts of leech and 5-10 parts of Tabanus, adding citric acid-disodium hydrogen phosphate buffer solution to adjust the pH value to 2-2.5, oscillating at constant temperature, adjusting the pH value to 4.5-5, adding a proper amount of extraction complex enzyme for enzymolysis, filtering, sequentially adding citric acid-disodium hydrogen phosphate buffer solution to filter residues to adjust the pH value to 7-7.5-8.5, performing water bath extraction, and combining all the extracting solutions to obtain an extracting solution A.
By adopting the technical scheme, the effective components in the leech and the gadfly are extracted by adopting a semi-bionic enzyme extraction method, the environment that the oral medicine is transported and absorbed through the gastrointestinal tract is simulated, the characteristics of traditional Chinese medicine compatibility and clinical medication and the characteristics of the oral medicine transported and absorbed in the gastrointestinal tract are better met, the absorption of the active components of the medicine by a patient is easy, and the treatment efficiency of the medicine is improved.
Preferably, the weight ratio of the extracted complex enzyme to the total mass of the raw materials is 1: (160-200).
By adopting the technical scheme, the compound enzyme is adopted, and the digestive enzyme active substances of the human body can be simulated, so that the extraction process is closer to the transportation and absorption process of the medicine in the gastrointestinal tract of the human body.
Preferably, the compound enzyme consists of the following enzymes in percentage by weight: 25-35% of chitinase, 20-35% of collagenase, 15-30% of trypsin and 20-40% of neutral protease.
By adopting the technical scheme, the chitin enzyme, the collagenase, the trypsin and the neutral protease are compounded, because a large amount of active ingredients cannot be extracted due to protein solidification when the animal medicine is decocted in water, the curative effect of the medicine is influenced, the compound enzyme is improved, the protein ingredients of leeches and gadflies can be hydrolyzed, the active ingredients in the leeches and the gadflies are completely released, and the absorption and utilization of the active ingredients by a human body are facilitated.
Preferably, the preparation of extract B comprises the following steps:
weighing 20-30 parts of rheum officinale and 20-30 parts of peach kernels, crushing and sieving to obtain mixed powder, putting the mixed powder into supercritical carbon dioxide extraction equipment, and extracting at the extraction temperature of 35-60 ℃, the extraction pressure of 15-20MPa, the separator pressure of 10-20MPa, the separator temperature of 50-60 ℃, the separation time of 2-4h and the carbon dioxide flow of 40-50L per hour to obtain extract B.
By adopting the technical scheme, the rhubarb and the peach kernel are extracted by adopting the supercritical carbon dioxide extraction method, because the supercritical carbon dioxide extraction technology is used for extracting at the temperature close to room temperature and under the carbon dioxide gas cage, the oxidation and the dissipation of heat-sensitive substances are effectively prevented, the purity and the active ingredients of the medicine extract are kept to the maximum extent, and the absorption and the utilization of the active ingredients by a human body are facilitated.
The application also provides a preparation method of the traditional Chinese medicine capsule for treating cerebral apoplexy, which adopts the following technical scheme:
a preparation method of a traditional Chinese medicine capsule for treating cerebral apoplexy comprises the following steps:
preparing an extracting solution A and an extracting solution B according to a formula and a preparation method, combining the extracting solution A and the extracting solution B, adding 10-20 parts of medicinal auxiliary materials, uniformly stirring, and drying in vacuum to obtain dry paste; pulverizing the dry extract, adding 4-6 parts of medicinal adjuvants, sieving, mixing, and making into capsule.
By adopting the technical scheme and adopting the pharmaceutic adjuvant, on one hand, the dilution effect is achieved, and meanwhile, the extraction liquid is favorably solidified; on the other hand, the medicinal auxiliary materials can be adopted to ensure the uniformity of the medicinal components when the granules are prepared by crushing and sieving.
Preferably, the pharmaceutic adjuvant comprises one or more of starch, dextrin, powdered sugar and lactose.
By adopting the technical scheme, one or more of starch, dextrin, powdered sugar and lactose are used as the pharmaceutic adjuvant, and the starch, the dextrin, the powdered sugar and the lactose have stable properties, do not act with active ingredients in medicinal materials, have good hygroscopicity and are beneficial to preparing uniformly dispersed traditional Chinese medicine granules.
Preferably, the optimal proportion of the capsule is as follows: the raw materials comprise an extracting solution A and an extracting solution B;
the extracting solution A comprises the following raw materials in parts by weight: 17 parts of leech and 7 parts of gadfly;
the extract B comprises the following raw materials in parts by weight: 25 parts of rhubarb and 25 parts of peach kernel.
By adopting the technical scheme and adopting the combination of the traditional Chinese medicinal materials, the effects of the medicaments generate a synergistic effect, so that the cerebral apoplexy can be effectively treated. The effects of the medicinal materials are as follows:
leech: can break stasis and promote water flow, and can be used for treating abdominal mass accumulation and bruise. The pharmacological action research finds that: hirudin can prevent the action of thrombin on fibrinogen and prevent blood coagulation. Can improve blood rheological property, reduce blood viscosity, and inhibit blood platelet aggregation; hirudin has anticoagulant effect and can be used for resisting thrombosis; it also has heart rate slowing and blood pressure lowering effects.
Tabanus: bitter taste, slight cold, removing blood stasis, breaking accumulation and restoring menstrual flow. It is indicated for abdominal mass, blood accumulation in the lower abdomen, amenorrhea due to blood stagnation, and blood stasis.
Rhubarb: bitter and cold in flavor, entering stomach, large intestine and liver meridians. Purge heat and unblock intestines, cool blood and remove toxicity, dispel stasis and dredge meridians. Purging heat-toxin, breaking stagnation and removing blood stasis. It is indicated for constipation due to excessive heat, delirium, food stagnation, fullness and distention, dysentery with early stage, tenesmus, stasis, amenorrhea, abdominal mass, epidemic heat, acute conjunctivitis, hematemesis, epistaxis, yang-yellow, edema, stranguria with turbid urine, carbuncle, abscess, furuncle, and injury due to fire and dampness.
Peach kernel: bitter and sweet in taste and mild in nature; it enters heart, liver and large intestine meridians. Promote blood circulation to remove blood stasis, moisten intestines to relieve constipation, relieve cough and relieve asthma. Mainly treats amenorrhea, dysmenorrheal, abdominal mass and lump, traumatic injury, intestinal dryness and constipation.
The traditional Chinese medicine composition has the effects of breaking blood and removing stasis, and clearing and activating the channels and collaterals, is mainly used for the recovery period of atherosclerotic thrombotic cerebral infarction, is distinguished by apoplexy in channels and collaterals and blood stasis symptoms in traditional Chinese medicine, and has the symptoms of hemiplegia, facial distortion, stiff tongue and difficulty in speaking or aphasia, hemianesthesia, dark tongue with ecchymosis, and deep, thin and wiry pulse.
In summary, the present application includes at least one of the following beneficial technical effects:
1. by adopting the technical scheme, different methods are adopted to extract the active ingredients of the medicinal materials, so that the active ingredients in the medicament are completely extracted, and the absorption of the active ingredients of the medicinal materials by a patient is facilitated, thereby improving the treatment effect of the medicament; 2. by adopting the technical scheme, the effective components in the leech and the gadfly are extracted by adopting a semi-bionic enzyme extraction method, the environment that the oral medicine is transported and absorbed through the gastrointestinal tract is simulated, the characteristics of traditional Chinese medicine compatibility and clinical medication and the characteristics of the oral medicine transported and absorbed in the gastrointestinal tract are better met, the absorption of the active components of the medicine by a patient is easy, and the treatment efficiency of the medicine is improved;
3. the traditional Chinese medicine composition has the effects of breaking blood and removing stasis, and clearing and activating the channels and collaterals, is used for the recovery period of atherosclerotic thrombotic cerebral infarction, is distinguished by apoplexy in channels and collaterals and blood stasis symptoms in traditional Chinese medical science, and has the symptoms of hemiplegia, facial distortion, stiff tongue with difficulty or no speech, hemianesthesia, dark tongue with ecchymosis, and deep, thin or deep and wiry pulse.
Detailed Description
The present application will be described in further detail with reference to examples.
Examples
Example 1
S1, weighing 100g of leech and 50g of Tabanus, adding a citric acid-disodium hydrogen phosphate buffer solution, adjusting the pH value to 2, oscillating at 50 ℃ and 120rpm for 2 hours at constant temperature, then adjusting the pH value to 4.5, adding 0.94g of extraction complex enzyme for enzymolysis for 60 minutes, wherein the extraction complex enzyme comprises 25% of chitinase, 25% of collagenase, 20% of trypsin and 30% of neutral protease, and filtering to obtain an extracting solution I; soaking the filter residue in citric acid-disodium hydrogen phosphate, adjusting pH to 7, extracting in water bath at 70 deg.C for 2 hr, and filtering to obtain extractive solution II; soaking the filter residue in citric acid-disodium hydrogen phosphate buffer solution, adjusting pH to 8, performing water bath extraction at 70 deg.C for 2 hr, filtering to obtain extract III, and mixing extracts I, II and III to obtain extract A;
s2, crushing 200g of rheum officinale and 200g of peach kernels, then sieving with a 60-mesh sieve to obtain mixed powder, putting the mixed powder into supercritical carbon dioxide extraction equipment, and extracting at the extraction temperature of 35 ℃, the extraction pressure of 15MPa, the pressure of a separator of 10MPa, the temperature of the separator of 50 ℃, the separation time of 2 hours and the carbon dioxide flow of 40L per hour to obtain extract B;
s3, combining the extract A and the extract B obtained in the previous step, adding 100g of medicinal auxiliary materials, stirring for 30min, and drying in vacuum at 50 ℃ to obtain dry paste; pulverizing the dry extract, adding 40g of medicinal auxiliary materials, sieving with a 60-mesh sieve, uniformly mixing, and encapsulating, wherein each granule contains 0.35 g of medicinal powder, and the medicinal auxiliary materials used in the embodiment are 50g of starch and 50g of dextrin.
Example 2
S1, weighing 170g of leech, 70g of gadfly, adding citric acid-disodium hydrogen phosphate buffer solution, adjusting the pH value to 2.2, oscillating at the constant temperature of 55 ℃ and 130rpm for 2.5h, then adjusting the pH value to 4.7, adding 1.69g of extraction complex enzyme for enzymolysis for 70min, wherein the extraction complex enzyme comprises 25% of chitinase, 25% of collagenase, 20% of trypsin and 30% of neutral protease, and filtering to obtain an extracting solution I; soaking the filter residue in citric acid-disodium hydrogen phosphate, adjusting pH to 7.3, extracting in water bath at 75 deg.C for 2.5 hr, and filtering to obtain extractive solution II; soaking the filter residue in citric acid-disodium hydrogen phosphate buffer solution, adjusting pH to 8.3, extracting at 75 deg.C in water bath for 2.5 hr, filtering to obtain extract III, and mixing the extracts I, II and III to obtain extract A;
s2, crushing 250g of rheum officinale and 250g of peach kernels, sieving the crushed materials with a 80-mesh sieve to obtain mixed powder, putting the mixed powder into supercritical carbon dioxide extraction equipment, and extracting at the extraction temperature of 50 ℃, the extraction pressure of 17MPa, the separator pressure of 15MPa, the separator temperature of 55 ℃, the separation time of 3 hours and the carbon dioxide flow rate of 45L per hour to obtain an extract B;
s3, combining the extract A and the extract B obtained in the step, adding 150g of medicinal auxiliary materials, stirring for 40min, and drying in vacuum at 60 ℃ to obtain dry paste; pulverizing the dry extract, adding 50g of medicinal auxiliary materials, sieving with a 80-mesh sieve, uniformly mixing, and encapsulating, wherein each granule contains 0.35 g of medicinal powder, and the medicinal auxiliary materials used in the embodiment are 50g of starch and 50g of dextrin.
Example 3
S1, weighing 250g of leech, adding 100g of gadfly into citric acid-disodium hydrogen phosphate buffer solution, adjusting the pH value to 2.5, oscillating at the constant temperature of 60 ℃ and 140rpm for 3 hours, then adjusting the pH value to 5, adding 2.19g of extraction complex enzyme for enzymolysis for 80min, wherein the extraction complex enzyme comprises 25% of chitinase, 25% of collagenase, 20% of trypsin and 30% of neutral protease, and filtering to obtain an extracting solution I; adding the filter residue into citric acid-disodium hydrogen phosphate, adjusting pH to 7.5, extracting with water bath at 80 deg.C for 3 hr, and filtering to obtain extractive solution II; adding the filter residue into citric acid-disodium hydrogen phosphate buffer solution, adjusting pH to 8.5, performing water bath extraction at 80 deg.C for 3 hr, filtering to obtain extract III, and mixing extract I, II and III to obtain extract A;
s2, crushing 300g of rheum officinale and 300g of peach kernels, sieving the crushed materials with a 100-mesh sieve to obtain mixed powder, putting the mixed powder into supercritical carbon dioxide extraction equipment, and extracting at the extraction temperature of 60 ℃, the extraction pressure of 20MPa, the separator temperature of 60 ℃, the separation time of 4 hours and the carbon dioxide flow of 50L per hour to obtain extract B;
s3, combining the extract A and the extract B obtained in the step, adding 200g of medicinal auxiliary materials, stirring for 50min, and drying in vacuum at 70 ℃ to obtain dry paste; pulverizing the dry extract, adding 60g of medicinal adjuvants, sieving with 120 mesh sieve, mixing, and encapsulating to obtain 0.35 g of medicinal powder per capsule, wherein the medicinal adjuvants used in this example are 100g of starch and 100g of dextrin.
Example 4
Example 4 differs from example 1 in that the mass of the extracted complex enzyme used in example 4 was 0.83g.
Example 5
Example 5 differs from example 1 in that the mass of the extracted complex enzyme used in example 5 was 0.75g.
Example 6
Example 6 differs from example 1 in that the extracted complex enzyme used in example 6 comprises 30% chitin enzyme, 20% collagenase, 30% trypsin, and 20% neutral protease.
Example 7
Example 7 differs from example 1 in that the extracted complex enzyme used in example 7 comprises 35% chitinase, 25% collagenase, 15% trypsin and 25% neutral protease.
Example 8
Example 8 is different from example 1 in that 100g of dextrin is used as a pharmaceutical excipient in example 8.
Example 9
Example 9 differs from example 1 in that the pharmaceutical excipients used in example 9 are 50g powdered sugar and 50g lactose
Comparative example
Comparative example 1
S1, weighing 60g of leech, 20g of gadfly, adding citric acid-disodium hydrogen phosphate buffer solution, adjusting the pH value to 1.8, oscillating at 45 ℃ for 1 hour at constant temperature of 100rpm, then adjusting the pH value to 4, adding 0.5g of extracted complex enzyme for enzymolysis for 50min, wherein the extracted complex enzyme comprises 25% of chitinase, 25% of collagenase, 20% of trypsin and 30% of neutral protease, and filtering to obtain an extracting solution I; soaking the filter residue in citric acid-disodium hydrogen phosphate, adjusting pH to 6.5, extracting in water bath at 60 deg.C for 1 hr, and filtering to obtain extractive solution II; soaking the filter residue in citric acid-disodium hydrogen phosphate buffer solution, adjusting pH to 7, performing water bath extraction at 60 deg.C for 1 hr, filtering to obtain extract III, and mixing extracts I, II and III to obtain extract A;
s2, crushing 150g of rheum officinale and 150g of peach kernels, sieving the crushed materials with a 40-mesh sieve to obtain mixed powder, putting the mixed powder into supercritical carbon dioxide extraction equipment, and extracting at the extraction temperature of 30 ℃, the extraction pressure of 12MPa, the separator pressure of 8MPa, the separator temperature of 40 ℃, the separation time of 1h and the carbon dioxide flow of 30L per hour to obtain an extract B;
s3, combining the extract A and the extract B obtained in the step, adding 70g of medicinal auxiliary materials, stirring for 20min, and drying in vacuum at 40 ℃ to obtain dry paste; pulverizing the dry extract, adding 20g of medicinal adjuvants, sieving with a 40-mesh sieve, mixing, and encapsulating to obtain 0.35 g of medicinal powder per capsule, wherein the medicinal adjuvants used in this example are 40g of starch and 30g of dextrin.
Comparative example 2
S1, weighing 300g of leech and 150g of Tabanus, adding citric acid-disodium hydrogen phosphate buffer solution, adjusting the pH value to 3, oscillating at 70 ℃ and 150rpm for 3.5 hours at constant temperature, then adjusting the pH value to 5.5, adding 2.81g of extraction complex enzyme for enzymolysis for 90min, wherein the extraction complex enzyme in the embodiment comprises 25% of chitinase, 25% of collagenase, 20% of trypsin and 30% of neutral protease, and filtering to obtain an extracting solution I; soaking the filter residue in citric acid-disodium hydrogen phosphate, adjusting pH to 8, extracting in water bath at 90 deg.C for 3.5 hr, and filtering to obtain extractive solution II; soaking the filter residue in citric acid-disodium hydrogen phosphate buffer solution, adjusting pH to 9, performing water bath extraction at 90 deg.C for 3.5 hr, filtering to obtain extract III, and mixing extracts I, II and III to obtain extract A;
s2, crushing 350g of rheum officinale and 350g of peach kernels, sieving the crushed materials with a 120-mesh sieve to obtain mixed powder, putting the mixed powder into supercritical carbon dioxide extraction equipment, and extracting at the extraction temperature of 70 ℃, the extraction pressure of 30MPa, the separator temperature of 70 ℃, the separation time of 5 hours and the carbon dioxide flow rate of 60L per hour to obtain extract B;
s3, combining the extract A and the extract B obtained in the step, adding 250g of medicinal auxiliary materials, stirring for 60min, and drying in vacuum at 80 ℃ to obtain dry paste; pulverizing the dry extract, adding 70g of medicinal adjuvants, sieving with a 130-mesh sieve, mixing, and encapsulating to obtain 0.35 g of medicinal powder, wherein the medicinal adjuvants used in the embodiment are 125g of starch and 125g of dextrin.
Comparative example 3
Comparative example 3 differs from example 1 in that the mass of the extracted complex enzyme used in comparative example 3 is 1.07g.
Comparative example 4
Comparative example 4 differs from example 1 in that comparative example 4 used 0.68g of extracted complex enzyme.
Comparative example 5
20g of leech, 15g of gadfly, 20g of rhubarb and 20g of peach kernel are dried in vacuum at 50 ℃, crushed, sieved by a 60-mesh sieve and encapsulated, and each capsule is 0.35 g of medicinal powder.
Performance test
1. Cell assay
1. Establishing a model:
after the plates were cultured for 24h, the culture medium was discarded from each well, and washed 2 times with sugar-free Earle's solution (sodium chloride 143mmol/L, potassium chloride 5.4mmol/L, calcium chloride 1.8mmol/L, magnesium sulfate 1.0mmol/L, sodium dihydrogen phosphate 1.0mmol/L, N-2 hydroxyethyl piperazine-N' -2 sulfonic acid ethane 2.4mmol/L, pH 7.4), DMEM medium without serum was added to normal control wells; adding Earle's solution containing sodium dithionite with final concentration of 1.0mmol/L into the model hole, incubating at 37 deg.C for 6h in a carbon dioxide incubator with volume fraction of 5%, taking out the culture plate, removing the liquid from each hole, washing cells with sugar-free Earle's solution for 2 times, changing serum-free DMEM culture solution, continuing culturing for 12h, and then feeding oxygen to damage the model.
2. Grouping experiments:
the groups were randomly divided into a normal culture control group, an oxygen-deficient and sugar-deficient group, examples 1 to 9 groups, and comparative examples 1 to 5 groups. The medicine is added into sugar-free Earle's solution containing 1.0mmol/L sodium dithionite and DMEM culture solution containing serum during oxygen-deficient and oxygen-supplying treatment, and the rest is the same as oxygen-deficient and sugar-deficient re-administration group.
3. The main observation indexes are as follows:
(ii) cell mortality; a lactate dehydrogenase; the rate of cell necrosis; the rate of apoptosis.
4. The specific detection method comprises the following steps:
1) The cell death rate was determined by trypan blue staining count.
2) And (3) measuring the leakage rate of the lactate dehydrogenase by using an ultraviolet spectrophotometry, collecting the supernatant of the culture plate in test tubes with corresponding numbers, adding 1mL of serum-free DMEM culture medium into the culture plate, and respectively storing the culture plate in a low-temperature refrigerator at the temperature of minus 86 ℃. Taking out when the determination is needed, and repeatedly freezing and thawing the cells in the holes for 2-3 times. The purpose is to break cells, evenly mix the cells, centrifuge the cells for 5min at the rotating speed of 3000r/min, and operate the cells according to the instructions of a lactate dehydrogenase kit. The lactate dehydrogenase activity in the supernatant and the corresponding cytoplasm was calculated at the wavelength of 340nm, from the average absorbance change per minute measured at this wavelength.
3) Detecting the necrosis rate and the apoptosis rate of the cells by using a Hoechst33342 and propidium iodide original-taste double-staining method, and observing the cells by using a fluorescence microscope during detection to find that normal cells show blue fluorescence and chromatin is uniformly distributed; although the apoptotic cells also showed blue fluorescence, chromatin aggregated, nuclei shriveled, and ruptured; whereas necrotic cells show blue fluorescence.
Specific detection results are shown in table 1:
TABLE 1
As can be seen from table 1 (P is less than 0.01), the formula and the proportion of the traditional Chinese medicine capsule for treating cerebral apoplexy provided by the application can obviously reduce the cell necrosis rate and the apoptosis rate of nerve cells during hypoxia, glucose deprivation and then oxygenation injury, obviously improve the cell survival rate of the nerve cells, reduce the leakage of lactate dehydrogenase, prevent the brain tissue from further injury after ischemic cerebral apoplexy by intervening the apoptosis process of the nerve cells, and thus play a role in protecting the neuronal injury.
As can be seen from the test results of examples 1,2,3 and comparative examples 1,2, example 2 is the most preferred example, and the cells have the lowest necrosis rate, apoptosis rate, survival rate and lactate dehydrogenase leakage rate.
As can be seen from the detection results of examples 1,4 and 5 and comparative examples 3 and 4, the protective effect on neuron injury tends to be enhanced first and then reduced when the dosage of the extracted complex enzyme is increased, and when the weight ratio of the extracted complex enzyme to the total mass of the raw materials is less than 1: at 160 deg.C, the cell death rate, necrosis rate, and apoptosis rate increased, and the lactate dehydrogenase leakage rate also increased.
The detection results of the embodiment 1,6,7 show that the formula and the proportion of the complex enzyme provided by the application and the extract liquid obtained by enzymolysis are beneficial to the protection effect on the neuron damage, and the change in the proportion range has little influence on the death rate, the necrosis rate, the apoptosis rate and the leakage rate of the lactate dehydrogenase of cells.
The detection results of the examples 1,8,9 show that the formulation and the proportion of the pharmaceutical excipients provided by the application are both beneficial to the protection effect on the neuronal damage, and the change of the formulation has little influence on the death rate, the necrosis rate, the apoptosis rate and the lactate dehydrogenase leakage rate of cells.
As can be seen from the detection results of the embodiment 1 and the comparative example 5, the effective components in the medicine are extracted, so that the cell necrosis rate and the apoptosis rate of the nerve cells during hypoxia, sugar deficiency and oxygen supply injury are obviously reduced compared with the medicine for direct crushing, the cell survival rate is obviously improved, the leakage of lactate dehydrogenase is reduced, and the protection effect on the neuron injury is improved.
2. Clinical trial
1. Case selection
400 cases are randomly selected in a hospital, 200 male and female patients are 200 cases respectively, the age is between 39 and 82 years, the average age is 57 years, and the patients select to have symptoms of hemiplegia, slurred speech, hemianopsia, hemidysesthesia, severe dizziness, vomiting and other cranial hypertension. And (3) performing craniocerebral CT examination, and removing cerebral hemorrhage by craniocerebral CT to diagnose patients suffering from cerebral apoplexy. The composition is divided into a treatment group and a control group at random, the treatment group is added with the capsule provided by the application on the basis of western medicine (example 2), and the control group is added with the Naoxuekang capsule on the basis of western medicine (Weishan lake pharmaceutical factory in Shandong province).
2. Method of treatment
A. Treatment groups: the capsule of the application is 4 capsules at a time, 2 times a day, and is used for intravenous injection of medicines for resisting platelet aggregation, reducing fiber and increasing cell metabolism (400 mg per day of injection for thromboembolism and 250ml of sodium chloride injection, 4-8g per time of piracetam injection, 1 time per day of 5% glucose injection, intravenous injection;
B. control group: naoxuekang capsule is 1 tablet at a time, 3 times a day, and is a medicine for intravenous injection (400 mg for injection, 250ml of sodium chloride injection and intravenous drip; 4-8g for one time of piracetam injection and 1 time a day of 5% glucose injection and intravenous drip) for intravenous drip.
3. Criteria for evaluating therapeutic effects
The treatment group and the control group are observed for 28 days; index and therapeutic effect determination standard: according to the indexes such as symptom and physical sign of patients in each course of treatment, the curative effect is divided into four levels of clinical cure, obvious effect, effective effect and ineffective effect:
basically curing: most symptoms disappear, and the life can be completely self-care;
the effect is shown: the symptoms are obviously improved, the muscle strength of the paralyzed limbs is improved by 2 grades, and the life can be self-managed;
the method has the following advantages: the symptoms are improved, and the muscle strength of limbs is improved by level 1;
and (4) invalidation: there was no significant change in symptoms and signs before and after treatment.
The specific results are shown in table 2:
TABLE 2
As can be seen from Table 2, the two groups of the Chinese medicinal capsules have extremely significant difference in curative effect, P is less than 0.01, the curative group is superior to the control group, and by using the Chinese medicinal capsules for treating cerebral apoplexy, the total effective rate reaches 100%, the cure rate reaches 32%, and the significant efficiency reaches 56.55%.
The present embodiment is only for explaining the present application, and it is not limited to the present application, and those skilled in the art can make modifications of the present embodiment without inventive contribution as needed after reading the present specification, but all of them are protected by patent law within the scope of the claims of the present application.
Claims (8)
1. A traditional Chinese medicine capsule for treating cerebral apoplexy is characterized in that: the raw materials comprise an extracting solution A and an extracting solution B;
the extracting solution A comprises the following raw materials in parts by weight: 10-25 parts of leech and 5-10 parts of gadfly;
the extract B comprises the following raw materials in parts by weight: 20-30 parts of rhubarb and 20-30 parts of peach kernel.
2. The traditional Chinese medicine capsule for treating cerebral apoplexy according to claim 1, wherein: the preparation of the extracting solution A comprises the following steps:
weighing 10-25 parts of leech and 5-10 parts of Tabanus, adding citric acid-disodium hydrogen phosphate buffer solution to adjust the pH value to 2-2.5, oscillating at constant temperature, adjusting the pH value to 4.5-5, adding a proper amount of extraction complex enzyme for enzymolysis, filtering, sequentially adding citric acid-disodium hydrogen phosphate buffer solution to filter residues to adjust the pH value to 7-7.5-8.5, performing water bath extraction, and combining all the extracting solutions to obtain an extracting solution A.
3. The traditional Chinese medicine capsule for treating cerebral apoplexy according to claim 2, wherein: the weight ratio of the extracted complex enzyme to the total mass of the raw materials is 1: (160-200).
4. The traditional Chinese medicine capsule for treating cerebral apoplexy according to claim 2, wherein: the compound enzyme consists of the following enzymes in percentage by weight: 25-35% of chitinase, 20-35% of collagenase, 15-30% of trypsin and 20-40% of neutral protease.
5. The traditional Chinese medicine capsule for treating cerebral apoplexy according to claim 1, wherein: the preparation of the extract B comprises the following steps:
weighing 20-30 parts of rheum officinale and 20-30 parts of peach kernels, crushing and sieving to obtain mixed powder, putting the mixed powder into supercritical carbon dioxide extraction equipment, and extracting at the extraction temperature of 35-60 ℃, the extraction pressure of 15-20MPa, the separator pressure of 10-20MPa, the separator temperature of 50-60 ℃, the separation time of 2-4h and the carbon dioxide flow of 40-50L per hour to obtain extract B.
6. A method for preparing the Chinese medicinal capsule for treating cerebral apoplexy according to any one of claims 1-5, which is characterized in that: the method comprises the following steps:
preparing an extracting solution A and an extracting solution B according to a formula and a preparation method, combining the extracting solution A and the extracting solution B, adding 10-20 parts of medicinal auxiliary materials, uniformly stirring, and drying in vacuum to obtain dry paste; pulverizing the dry extract, adding 4-6 parts of medicinal adjuvants, sieving, mixing, and making into capsule.
7. The preparation method of the traditional Chinese medicine capsule for treating cerebral apoplexy according to claim 6, wherein the preparation method comprises the following steps: the medicinal adjuvants include one or more of starch, dextrin, sugar powder, and lactose.
8. The preparation method of the traditional Chinese medicine capsule for treating cerebral apoplexy according to claim 6, wherein the preparation method comprises the following steps: the optimal proportion of the capsule is as follows: the raw materials comprise an extracting solution A and an extracting solution B;
the extracting solution A comprises the following raw materials in parts by weight: 17 parts of leech and 7 parts of gadfly;
the extract B comprises the following raw materials in parts by weight: 25 parts of rhubarb and 25 parts of peach kernel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211668761.5A CN115813985B (en) | 2022-12-24 | 2022-12-24 | A Chinese medicinal capsule for treating cerebral apoplexy, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211668761.5A CN115813985B (en) | 2022-12-24 | 2022-12-24 | A Chinese medicinal capsule for treating cerebral apoplexy, and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115813985A true CN115813985A (en) | 2023-03-21 |
| CN115813985B CN115813985B (en) | 2024-03-12 |
Family
ID=85518112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211668761.5A Active CN115813985B (en) | 2022-12-24 | 2022-12-24 | A Chinese medicinal capsule for treating cerebral apoplexy, and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115813985B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1506097A (en) * | 2002-12-10 | 2004-06-23 | 浙江得恩德制药有限公司 | Chinese medicine capsule for treating ischemic cerebral apoplexy |
| CN102225076A (en) * | 2011-06-14 | 2011-10-26 | 重庆时珍阁普生药业有限公司 | Modified Maixuekang preparation, modified Maixuekang enteric-coated preparation as well as preparation methods and applications thereof |
| CN102335370A (en) * | 2011-09-30 | 2012-02-01 | 哈药集团三精千鹤制药有限公司 | Flavored medicinal composition for removing stasis and dredging collaterals, and preparation method thereof |
| CN102362905A (en) * | 2011-11-09 | 2012-02-29 | 哈药集团三精千鹤制药有限公司 | Method for preparing capsules for removing stasis and unblocking channels |
| CN103505532A (en) * | 2013-10-10 | 2014-01-15 | 北京康远制药有限公司 | Traditional Chinese medicinal granules capable of removing blood stasis and preparation method thereof |
-
2022
- 2022-12-24 CN CN202211668761.5A patent/CN115813985B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1506097A (en) * | 2002-12-10 | 2004-06-23 | 浙江得恩德制药有限公司 | Chinese medicine capsule for treating ischemic cerebral apoplexy |
| CN102225076A (en) * | 2011-06-14 | 2011-10-26 | 重庆时珍阁普生药业有限公司 | Modified Maixuekang preparation, modified Maixuekang enteric-coated preparation as well as preparation methods and applications thereof |
| CN102335370A (en) * | 2011-09-30 | 2012-02-01 | 哈药集团三精千鹤制药有限公司 | Flavored medicinal composition for removing stasis and dredging collaterals, and preparation method thereof |
| CN102362905A (en) * | 2011-11-09 | 2012-02-29 | 哈药集团三精千鹤制药有限公司 | Method for preparing capsules for removing stasis and unblocking channels |
| CN103505532A (en) * | 2013-10-10 | 2014-01-15 | 北京康远制药有限公司 | Traditional Chinese medicinal granules capable of removing blood stasis and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 程凤飞: "从中成药分类论脑中风的分证论治", 中国社区医师(医学专业半月刊), no. 05, pages 42 - 43 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115813985B (en) | 2024-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016015391A1 (en) | Pharmaceutical composition for treating cardiovascular or cerebrovascular diseases and preparation method therefor | |
| CN103505600A (en) | Traditional Chinese medicinal granules capable of removing blood stasis and relieving pain and preparation method thereof | |
| CN103007000A (en) | New medicine for treating burns and wounds and preparation method thereof | |
| WO2019218103A1 (en) | Pharmaceutical composition with functions of removing cyst and protecting gastric mucosa, and preparation method therefor | |
| CN115813985B (en) | A Chinese medicinal capsule for treating cerebral apoplexy, and its preparation method | |
| CN107158225A (en) | A kind of Shengmai Yin composition and its preparation method and application | |
| CN102423328A (en) | Traditional Chinese medicine composition for treating cerebral apoplexy and its preparation method | |
| CN111558019B (en) | Traditional Chinese medicine composition with effects of benefiting qi, nourishing blood, regulating menstruation and relieving pain and preparation method and application thereof | |
| CN103735880A (en) | Traditional Chinese medicine for treating hypertension and hyperglycemia and preparation method thereof | |
| CN101152223B (en) | Use of poplar leaf phenols extract in preparation of medicine for treating cardiovascular disease | |
| CN100528186C (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN108904714B (en) | Preparation method of traditional Chinese medicine for treating cardiovascular diseases | |
| CN103405501A (en) | Preparation method of three-component blood-activating and stasis-dissolving capsules | |
| CN108210557B (en) | Edible biological product for eliminating flatulence, repairing and nursing gastric mucosa | |
| CN108743757A (en) | A kind of Chinese medicine composition and the preparation method and application thereof for treating insomnia | |
| CN113750187A (en) | A formula containing Garcinia cambogia and Hibiscus sabdariffa for preventing and treating renal calculus | |
| CN111150774A (en) | Application of black nightshade fruit in preventing and treating new coronavirus or influenza virus infection | |
| CN112076305A (en) | A Chinese medicinal oral and topical stock solution mixture for treating metabolic syndrome and resisting bacteria and inflammation | |
| CN104524461A (en) | Medicine composition for treating myocarditis and application thereof | |
| CN103800744A (en) | Acne removing composition prepared from medicine-food homologous medicinal materials fully | |
| CN107137567A (en) | Cherry freeze-dried powder freezes compound powder and the application in anti-gout drugs are prepared with smilax | |
| CN108938672B (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation for rehabilitation treatment of ischemic cerebral apoplexy | |
| CN108186921A (en) | A kind of antitumor Chinese medicine composition containing selenium and preparation method thereof | |
| CN110151922B (en) | Traditional Chinese medicine composition for treating angina pectoris complicated with hypertension and preparation method thereof | |
| CN1692916A (en) | Pharmaceutical prepn. of compound mannite, and its prepn. method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |